Rebecca R. Hung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rebecca R. Hung has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Rosenzweig
Stanley and Judith Frankel Institute for Heart and Brain Health, University of Michigan Medical Center, Ann Arbor, MI, USA
1 shared publication - Dan M. Roden
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
1 shared publication - Douglas Marshall Brinkley
Department of Medicine, Vanderbilt University Medical Center, Nashville, USA
1 shared publication Jacopo Gianetti
Program in Cardiovascular Gene Therapy, Cardiovascular Research Center, Massachusetts General Hospital-East, Charlestown, MA, and Harvard Medical School, Boston, MA, USA, Massachusetts General Hospital, Boston, MA 02114, USA, C.N.R. Pisa, Italy, Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA
1 shared publication- James Lukas Laws
Vanderbilt University Medical Center
1 shared publication Jr. Michael A. Gimbrone
Cardiovascular Research Center, Massachusetts General Hospital-East, Charlestown, MA, and Harvard Medical School, Boston, MA, USA, Massachusetts General Hospital, Boston, MA 02114, USA, C.N.R. Pisa, Italy, Vascular Research Division, Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA
1 shared publication
Latest Publications
- 26 May 2022
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 130 (11) , 1698-1722
Arrhythmias as Presentation of Genetic Cardiomyopathy
There is increasing evidence regarding the prevalence of genetic cardiomyopathies, for which arrhythmias may be the first presentation. Ventricular and atrial arrhythmias presenting in the absence of known myocardial disease are often labelled as idiopathic, or lone. While ventricular arrhythmias are well-recognized as presentation for arrhythmogenic cardiomyopathy in the right ventricle, the scope of arrhythmogenic cardiomyopathy has broadened to include those with dominant left ventricular involvement, usually with a phenotype of dilated cardiomyopathy. In addition, careful evaluation for genetic cardiomyopathy is also warranted for patients presenting with frequent premature ventricular contractions, conduction system disease, and early onset atrial fibrillation, in which most detected genes are in the cardiomyopathy panels. Sudden death can occur early in the course of these genetic cardiomyopathies, for which risk is not adequately tracked by left ventricular ejection fraction. Only a few of the cardiomyopathy genotypes implicated in early sudden death are recognized in current indications for implantable cardioverter defibrillators which otherwise rely upon a left ventricular ejection fraction ≤0.35 in dilated cardiomyopathy. The genetic diagnoses impact other aspects of clinical management such as exercise prescription and pharmacological therapy of arrhythmias, and new therapies are coming into clinical investigation for specific genetic cardiomyopathies. The expansion of available genetic information and implications raises new challenges for genetic counseling, particularly with the family member who has no evidence of a cardiomyopathy phenotype and may face a potentially negative impact of a genetic diagnosis. Discussions of risk for both probands and relatives need to be tailored to their numeric literacy during shared decision-making. For patients presenting with arrhythmias or cardiomyopathy, extension of genetic testing and its implications will enable cascade screening, intervention to change the trajectory for specific genotype-phenotype profiles, and enable further development and evaluation of emerging targeted therapies.
- 26 May 2022
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 130 (11) , 1698-1722
Arrhythmias as Presentation of Genetic Cardiomyopathy
There is increasing evidence regarding the prevalence of genetic cardiomyopathies, for which arrhythmias may be the first presentation. Ventricular and atrial arrhythmias presenting in the absence of known myocardial disease are often labelled as idiopathic, or lone. While ventricular arrhythmias are well-recognized as presentation for arrhythmogenic cardiomyopathy in the right ventricle, the scope of arrhythmogenic cardiomyopathy has broadened to include those with dominant left ventricular involvement, usually with a phenotype of dilated cardiomyopathy. In addition, careful evaluation for genetic cardiomyopathy is also warranted for patients presenting with frequent premature ventricular contractions, conduction system disease, and early onset atrial fibrillation, in which most detected genes are in the cardiomyopathy panels. Sudden death can occur early in the course of these genetic cardiomyopathies, for which risk is not adequately tracked by left ventricular ejection fraction. Only a few of the cardiomyopathy genotypes implicated in early sudden death are recognized in current indications for implantable cardioverter defibrillators which otherwise rely upon a left ventricular ejection fraction ≤0.35 in dilated cardiomyopathy. The genetic diagnoses impact other aspects of clinical management such as exercise prescription and pharmacological therapy of arrhythmias, and new therapies are coming into clinical investigation for specific genetic cardiomyopathies. The expansion of available genetic information and implications raises new challenges for genetic counseling, particularly with the family member who has no evidence of a cardiomyopathy phenotype and may face a potentially negative impact of a genetic diagnosis. Discussions of risk for both probands and relatives need to be tailored to their numeric literacy during shared decision-making. For patients presenting with arrhythmias or cardiomyopathy, extension of genetic testing and its implications will enable cascade screening, intervention to change the trajectory for specific genotype-phenotype profiles, and enable further development and evaluation of emerging targeted therapies.
- 1 March 2002
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 34 (3) , 349-359
Endothelial IKK β Signaling is Required for Monocyte Adhesion under Laminar Flow Conditions
- 1 March 2002
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 34 (3) , 349-359
Endothelial IKK β Signaling is Required for Monocyte Adhesion under Laminar Flow Conditions